Esox Biologics focuses on developing innovative biopharmaceuticals that leverage advanced technologies in the field of biologics. The company specializes in the creation of monoclonal antibodies and other therapeutic proteins, utilizing cutting-edge techniques to enhance efficacy and safety. Their pipeline includes a range of products aimed at addressing unmet medical needs, particularly in the areas of oncology and autoimmune diseases. By employing state-of-the-art methodologies, Esox Biologics aims to streamline the drug development process and bring effective treatments to market more efficiently.

In addition to monoclonal antibodies, Esox Biologics is committed to utilizing next-generation sequencing and bioinformatics to optimize their therapeutic candidates. This approach allows for a deeper understanding of target interactions and the biological mechanisms underlying disease processes. The integration of these technologies not only accelerates the discovery phase but also supports the development of personalized medicine strategies, ensuring that treatments are tailored to the specific needs of patients. Through these innovative technologies, Esox Biologics is positioned to make significant contributions to the field of biopharmaceuticals.

United Kingdom

Esox Biologics utilises their extensive knowledge of the aquatic microbiome to provide disease prevention solutions that help improve livestock health and welfare.

Esox Biologics

Company Details